89
Participants
Start Date
October 27, 2021
Primary Completion Date
October 15, 2024
Study Completion Date
October 15, 2024
E7386
E7386 tablet.
Pembrolizumab
Pembrolizumab IV infusion.
Lenvatinib
Lenvatinib capsule.
Icahn School of Medicine at Mount Sinai, New York
Emory University, Atlanta
SCRI Florida Cancer Specialists East, West Palm Beach
Florida Cancer Specialists, Fort Myers
Sarah Cannon Cancer Care in Nashville, Nashville
Barbara Ann Karmanos Cancer Center, Detroit
University of California, Los Angeles, Los Angeles
University of California, Irvine Health, Orange
Providence Medical Center, Portland
Rutgers cancer Institute of NJ, New Brunswick
Chiba University Hospital, Chiba
National Cancer Center Hospital, Chūōku
Kurume University Hospital, Fukuoka
National Cancer Center Hospital East, Kashiwa
Kindai University Hospital, Osaka
Osaka Metropolitan University Hospital, Osaka
Sapporo-Kosei General Hospital, Sapporo
Shizuoka Cancer Center Hospital, Shizouka
Toranomon Hospital, Tokyo
Hospital Regional Universitario de Malaga, Málaga
Hospital Clínico San Carlos, Madrid
Clínica Universidad de Navarra, Pamplona
Hospital Universitario de Badajoz, Badajoz
Hospital Clinic de Barcelona, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Hospital General Universitario Gregorio Maranon, Madrid
Hospital Universitario de la Paz, Madrid
Consorcio Hospital General Universitario de Valencia, Valencia
The Royal Marsden NHS Foundation Trust - The Royal Marsden Hospital, Sutton
Beatson West of Scotland Cancer Centre, Glasgow
Imperial College London, London
Royal Free Hospital NHS Foundation Trust, London
The Christie NHS Foundation Trust, Manchester
Merck Sharp & Dohme LLC
INDUSTRY
Eisai Inc.
INDUSTRY